Bylvay (odevixibat) – which Ipsen acquired when it took over US biotech Albireo in a $952 million deal in 2023 – was being ...

Sanofi has retreated from a plan to file its anti-OX40L antibody amlitelimab for approval as a treatment for atopic ...

In transfusion medicine, “wrong blood in tube” is not simply a paperwork issue: a misidentified blood group can lead to a ...

Against the advice of FDA staff scientists, an advisory committee has narrowly voted in support of looser restrictions on ...

In the phase 3 MonumenTAL-6 trial, Tecvayli (teclistamab) and Talvey (talquetamab) cut the risk of disease progression or death by 89% compared to standard-of-care combinations used as second- to ...

The FDA has named Dexcom as the first medical device manufacturer that will take part in a pilot programme that could make it ...

Armed with new pivotal trial results, Eli Lilly plans to file for approval of its keenly anticipated new weight-loss therapy, ...

The EU has delivered some good news to AstraZeneca's oncology business, approving its oral selective oestrogen receptor degrader (SERD) for breast cancer, even as it faces obstacles on its path to ...

GSK has won FDA approval for Jideytro, a drug at the heart of its $10.6 billion acquisition of Nuvalent earlier this year – ...

After a delay of several years, people living with multiple sclerosis in England will finally be able to get NHS access to ...

China has become the first country to approve Takeda's first-in-class orexin agonist, oveporexton, for the sleep disorder ...

The intense rivalry between Novo Nordisk and Eli Lilly in the market for GLP-1 agonist-based therapies for obesity and type 2 ...